Asset
SAPANISERTIB
Faeth Therapeutics Inc. Common Stock
Revenue
No revenue reported in loaded filings.
Clinical trials (3)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT05275673 | phase2 | terminated | 2022-07-21 | 2023-01-24 | Faeth Therapeutics | A Study of Sapanisertib in Relapsed/Refractory NFE2L2-Mutated and Wild-Type Squamous Non-Small Cell Lung Cancer |
| NCT06463028 | phase2 | recruiting | 2024-12-12 | 2028-09-01 | Faeth Therapeutics | Sapanisertib and Serabelisib (PIKTOR) With Paclitaxel and a Substudy With an Insulin-Suppressing Diet in Patients With Advanced/Recurrent Endometrial Cancer |
| NCT07558733 | phase1_2 | recruiting | 2026-04-22 | 2029-05-01 | Faeth Therapeutics | Sapanisertib and Serabelisib (PIKTOR) in Various Combinations in Patients With HR+/HER2- Advanced/Metastatic Breast Cancer |
FDA applications (0)
This company has no applications containing this asset.